255 related articles for article (PubMed ID: 19443972)
1. Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia.
Nanri K; Okita M; Takeguchi M; Taguchi T; Ishiko T; Saito H; Otsuka T; Mitoma H; Koizumi K
Intern Med; 2009; 48(10):783-90. PubMed ID: 19443972
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Autoantibodies and the Efficacy of Immunotherapy for Autoimmune Cerebellar Ataxia.
Nanri K; Okuma M; Sato S; Yoneda M; Taguchi T; Mitoma H; Yamada J; Unezaki S; Nagatani T; Otsubo S; Sugawara M; Tanaka N; Mizusawa H
Intern Med; 2016; 55(5):449-54. PubMed ID: 26935362
[TBL] [Abstract][Full Text] [Related]
3. Cerebellar ataxia associated to anti-glutamic acid decarboxylase autoantibody (anti-GAD): partial improvement with intravenous immunoglobulin therapy.
Pedroso JL; Braga-Neto P; Dutra LA; Barsottini OG
Arq Neuropsiquiatr; 2011 Dec; 69(6):993. PubMed ID: 22297896
[No Abstract] [Full Text] [Related]
4. Gluten ataxia in Japan.
Nanri K; Mitoma H; Ihara M; Tanaka N; Taguchi T; Takeguchi M; Ishiko T; Mizusawa H
Cerebellum; 2014 Oct; 13(5):623-7. PubMed ID: 24997752
[TBL] [Abstract][Full Text] [Related]
5. [A case of anti-gliadin-antibody-positive cerebellar ataxia effectively treated with intravenous immunoglobulin in which voxel-based morphometry and FineSRT were diagnostically useful].
Nanri K; Otsuka T; Takeguchi M; Taguchi T; Ishiko T; Mitoma H; Koizumi K
Rinsho Shinkeigaku; 2009 Jan; 49(1):37-42. PubMed ID: 19227895
[TBL] [Abstract][Full Text] [Related]
6. [Cerebellar Ataxia and Autoantibodies].
Nanri K; Yoshikura N; Kimura A; Nakayama S; Otomo T; Shimohata T; Terashi H; Sato T; Yamada J
Brain Nerve; 2018 Apr; 70(4):371-382. PubMed ID: 29632285
[TBL] [Abstract][Full Text] [Related]
7. Cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
Abele M; Weller M; Mescheriakov S; Bürk K; Dichgans J; Klockgether T
Neurology; 1999 Mar; 52(4):857-9. PubMed ID: 10078741
[TBL] [Abstract][Full Text] [Related]
8. Cerebellar ataxia and epilepsy with anti-GAD antibodies: treatment with IVIG and plasmapheresis.
Georgieva Z; Parton M
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24419643
[TBL] [Abstract][Full Text] [Related]
9. [Case of anti-TPO/gliadin antibody-positive cerebellar atrophy that responded to intravenous immunoglobulin therapy begun 16 years after onset].
Tanaka N; Otake H; Ito S; Niiyama K; Nanri K
Rinsho Shinkeigaku; 2012; 52(5):351-5. PubMed ID: 22688115
[TBL] [Abstract][Full Text] [Related]
10. Low-titer anti-GAD-antibody-positive cerebellar ataxia.
Nanri K; Niwa H; Mitoma H; Takei A; Ikeda J; Harada T; Okita M; Takeguchi M; Taguchi T; Mizusawa H
Cerebellum; 2013 Apr; 12(2):171-5. PubMed ID: 22923147
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
Planche V; Marques A; Ulla M; Ruivard M; Durif F
Cerebellum; 2014 Jun; 13(3):318-22. PubMed ID: 24218114
[TBL] [Abstract][Full Text] [Related]
12. [Usefulness of an anti-mouse cerebellar tissue-derived antigen antibody test in predicting immunotherapy efficacy in patients with idiopathic cerebellar ataxia].
Ohtomo T; Ogino S; Yanai S; Nakayama S; Yajima R; Sugawara M; Yamada J; Aizawa H; Taguchi T; Nanri K
Rinsho Shinkeigaku; 2022 Feb; 62(2):112-122. PubMed ID: 35095045
[TBL] [Abstract][Full Text] [Related]
13. GABA-A receptor impairment in cerebellar ataxia with anti-glutamic acid decarboxylase antibodies.
Hosoi Y; Suzuki-Sakao M; Terada T; Konishi T; Ouchi Y; Miyajima H; Kono S
J Neurol; 2013 Dec; 260(12):3086-92. PubMed ID: 24091766
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of patients with cerebellar ataxia associated with anti-GAD antibodies.
Aguiar TS; Fragoso A; Albuquerque CR; Teixeira PF; Souza MV; Zajdenverg L; Alves-Leon SV; Rodacki M; Lima MA
Arq Neuropsiquiatr; 2017 Mar; 75(3):142-146. PubMed ID: 28355320
[TBL] [Abstract][Full Text] [Related]
15. Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
Jones AL; Flanagan EP; Pittock SJ; Mandrekar JN; Eggers SD; Ahlskog JE; McKeon A
JAMA Neurol; 2015 Nov; 72(11):1304-12. PubMed ID: 26414229
[TBL] [Abstract][Full Text] [Related]
16. Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.
Petrijan T; Menih M
Cerebellum; 2017 Aug; 16(4):868-871. PubMed ID: 28321713
[TBL] [Abstract][Full Text] [Related]
17. Auto-immune cerebellar ataxia with anti-GAD antibodies accompanied by de novo late-onset type 1 diabetes mellitus.
Bayreuther C; Hieronimus S; Ferrari P; Thomas P; Lebrun C
Diabetes Metab; 2008 Sep; 34(4 Pt 1):386-8. PubMed ID: 18583169
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity.
Saiz A; Arpa J; Sagasta A; Casamitjana R; Zarranz JJ; Tolosa E; Graus F
Neurology; 1997 Oct; 49(4):1026-30. PubMed ID: 9339684
[TBL] [Abstract][Full Text] [Related]
19. Lesson of the month 2: Autoimmune sequelae of anti-GAD antibodies - thinking outside the box.
Ward RJ; Varughese GI; Jose B; Abraham RJ
Clin Med (Lond); 2017 Oct; 17(5):473-474. PubMed ID: 28974603
[TBL] [Abstract][Full Text] [Related]
20. Anti-glutamic acid decarboxylase (GAD) positive cerebellar Ataxia with transitioning to progressive encephalomyelitis with rigidity and myoclonus (PERM), responsive to immunotherapy: A case report and review of literature.
Jazebi N; Rodrigo S; Gogia B; Shawagfeh A
J Neuroimmunol; 2019 Jul; 332():135-137. PubMed ID: 31015081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
